A recent investigation by the Food and Drug Administration (FDA) has revealed a concerning possibility: CAR-T therapies, which have been hailed as a breakthrough in treating terminal blood cancers, may inadvertently lead to the development of new cancers in patients undergoing the treatment. CAR-T therapy involves extracting immune cells from a patient’s body, modifying them to target tumors,...